Altamira Therapeutics Ltd. (CYTOF)
| Market Cap | 377.79K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.46M |
| Shares Out | 5.72M |
| EPS (ttm) | -2.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,200 |
| Average Volume | 5,740 |
| Open | 0.0900 |
| Previous Close | 0.0700 |
| Day's Range | 0.0660 - 0.0900 |
| 52-Week Range | 0.0501 - 0.4300 |
| Beta | 2.67 |
| RSI | 44.90 |
| Earnings Date | Sep 18, 2025 |
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II cli... [Read more]
Financial Performance
Financial StatementsNews
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine
HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet med...
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
Hamilton, May 27, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira's RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing...
Altamira Therapeutics Ltd. (CYTOF) Q4 2024 Earnings Call Transcript
Altamira Therapeutics Ltd. (OTC:CYTOF) Q4 2024 Earnings Call April 30, 2025 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Paneda - Chief Operat...
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications...
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Hamilton, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery techno...
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent ...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technolo...
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technol...
Altamira Therapeutics Provides Update on Nasdaq Listing
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Li...
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained ex...
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Paneda...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technol...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA deliv...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technol...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery techno...
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery techno...
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therap...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed w...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its pres...
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technolo...
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technolo...
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technolo...
Altamira Therapeutics Provides Business Update
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and com...
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMIL TON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and c...
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and comm...